[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sepsis-induced-myocardial-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sepsis-induced-myocardial-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100568832","phase-2-the-treatment-of-sepsis-induced-myocardial-dysfunction-with-yiqilishui-formula-100568832",false,"NCT06686355","The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula","Double-blind Randomized Parallel Contrast Clinical Study of Yiqilishui Formula on Sepsis Induced Myocardial Dysfunction","YQSIMD","Inclusion Criteria\n\n1. Patients hospitalized in the ICU of Tongzhou Traditional Chinese Medicine Hospital and Dongzhimen Hospital of Beijing University of Chinese Medicine between January 2024 and December 2026.\n2. Patients diagnosed with SIMD and qi deficiency and water flooding syndrome.\n3. Aged 50 to 85 years.\n4. SOFA score: 2 to 12 points.\n5. Diagnosis of SIMD within 24 hours.\n6. Signed informed consent by the patient or their family.\n\nExclusion Criteria\n\n1. Subjects diagnosed with acute coronary syndrome.\n2. Subjects with heart failure caused by cardiomyopathies such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, or hypothyroid cardiomyopathy.\n3. Subjects with heart failure caused by structural heart abnormalities, arrhythmias, pulmonary heart disease, or cardiorenal syndrome.\n4. Subjects with severe primary diseases affecting survival, including uncontrolled, unresectable metastatic malignant tumors, hematologic diseases, and HIV.\n5. Subjects with liver or kidney dysfunction, with an individual SOFA score of ≥3 for liver or kidney function.\n6. Subjects who have used immunosuppressants continuously in the last 6 months or have undergone organ transplantation.\n7. Subjects who have used corticosteroids (equivalent to methylprednisolone ≥20mg\u002Fday) continuously within 7 days prior to enrollment.\n8. Subjects who have used Chinese herbal medicines or Chinese patent medicine replenishing qi, activating blood circulation and facilitating diuresis within 14 days prior to enrollment.\n9. Subjects deemed unable to take decoctions by clinicians.\n10. Pregnant or breastfeeding women.\n11. Subjects who have participated in other clinical trials within the last 30 days.\n12. Subjects deemed unable to complete or unsuitable for this study by the researchers (e.g., expected death within 48 hours or refusal of active treatment).","ALL","50 Years","85 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to learn if Chinese medicine - Yiqilishui formula works to treat sepsis-induced myocardial dysfunction (SIMD). It will also learn about the safety of Yiqilishui formula. The main questions it aims to answer are:\n\n* Compared with conventional western traetment alone, can supplementing conventional Western treatment with Yiqilishui formula better improve the heart function and reduce mortality of participants with SIMD?\n* What medical problems do participants have when taking Yiqilishui formula? Researchers will compare Yiqilishui formula to a placebo (a look-alike substance that contains no drug) to see if Yiqilishui formula works to treat SIMD.\n\nParticipants will:\n\n* Take Yiqilishui formula granules or placebo twice daily for 7 days, while receiving standard conventional Western treatment.\n* Undergo blood drawing, electrocardiogram and transthoracic echocardiography at enrollment, on the 3rd day, the 7th day, and the 14th day after enrollment.",[28],"Sepsis Induced Myocardial Dysfunction",[30,31,32,33,34,35],"sepsis","myocardial dysfunction","SIMD","Yiqilishui formula","Double-blind randomized","clinical study","RECRUITING","2026-03-25",{"date":39,"type":40},"2026-03-30","ACTUAL",{"date":42,"type":40},"2024-11-20",{"date":44,"type":22},"2026-12-31",{"name":46,"class":47},"Dongzhimen Hospital, Beijing","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100631166","sepsis-induced-myocardial-injury-in-critically-ill-children-100631166","NCT07497139","Sepsis Induced Myocardial Injury in Critically Ill Children","Predictors and Outcome Of Sepsis Induced Myocardial Injury In Critically Ill Children; A Prospective Observational Study","Inclusion Criteria:\n\n1. Pediatric population aged 1month to 18 years.\n2. Critically ill children (who has an illness or injury impairing one or more vital organ systems such that there is high probability of imminent or life-threatening deterioration in the patient's condition)\n3. Has clinically and laboratory manifestations of sepsis\n\nExclusion Criteria:\n\n1. Neonates and adults ( \\\u003C1 month or \\>18 years)\n2. Children with congenital heart disease\n3. Children with Acquired heart disease ( Rheumatic, Myocarditis or Cardiomyopathy)\n4. Cardiac surgery","1 Month","18 Years",{"count":59,"type":22},84,"OBSERVATIONAL","Sepsis is a dysregulated immune response due to infection, leading to life-threatening organ dysfunction affecting respiratory, renal, immunological, digestive, neurological, and cardiovascular organs. The prevalence of cardiovascular dysfunction caused by sepsis may reach up to 50%, and the symptoms may comprise vasodilatory shock, myocardial injury, arrhythmia, and sepsis-induced cardiomyopathy. (1) Sepsis-induced cardiomyopathy occurs frequently in critically ill patients, but the clinical features and prognostic impact of sepsis-induced cardiomyopathy on sepsis outcome remain controversial.\n\nCardiac troponins I and T are regulatory proteins that control the calcium-mediated interaction of actin and myosin, producing myocardial contraction. Since troponins do not occur in extracellular space, their appearance in serum is sensitive and specific marker of myocardium damage. They have been established as the gold standard biochemical markers for myocardial necrosis .\n\nElevated cardiac troponins levels have been detected in critically ill children with congenital heart disease before and after cardiac surgery.(2) Echocardiography is the cornerstone for the diagnosis of septic cardiomyopathy. There is consensus and expert opinion that every hemodynamically unstable patient should receive critical care echocardiography.(3) Improved understanding of sepsis induced myocardial injury is important for multiple reasons. First, cardiac function is crucial for maintaining hemodynamic stability in patients with septic shock. Second, by understanding the clinical features and predictors of sepsis induced myocardial injury, the investigators can discriminate sepsis-induced cardiomyopathy from other cardiac diseases and avoid unnecessary invasive procedures, such as coronary angiography, a risky procedure in critically ill patients. Thus, the investigators aimed to define clinical predictors of sepsis-induced cardiomyopathy and assess the clinical course and outcome of sepsis-induced cardiomyopathy in patients with sepsis.",[63,28],"Sepsis Induced Cardiomyopathy","NOT_YET_RECRUITING","2026-03-23",{"date":67,"type":40},"2026-03-27",{"date":69,"type":22},"2026-04-01",{"date":71,"type":22},"2028-04-01",{"name":73,"class":47},"Assiut University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100621841","phase-2-investigating-the-clinical-benefits-and-underlying-mechanisms-of-danhong-injection-in-modulating-mitochondrial-homeostasis-against-sepsis-associated-myocardial-dysfunction-100621841","NCT07375862","Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction","Inclusion Criteria:\n\n1. Patients who met the Sepsis-3 criteria, defined by a suspected or confirmed infection and an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more from baseline.\n2. Patients with a diagnosis of sepsis-induced myocardial dysfunction (SIMD).\n\nExclusion Criteria:\n\n1. Patients with significant primary cardiac diseases, including unstable coronary artery disease, severe cardiomyopathy, or severe valvular heart disease.\n2. Exclusion criteria included long-term use of Danhong Injection or recent use of other medication with potential significant impact on cardiac function.\n3. Patients with severe hepatic dysfunction (defined as Child-Pugh class C) or severe renal insufficiency (defined as creatinine clearance \\\u003C30 mL\u002Fmin) were excluded.\n4. Patients with a known allergy to any component of Danhong Injection or a history of severe allergic diathesis were excluded.\n5. Pregnant or lactating women\n6. Patients with severe mental illness or inability to cooperate with the study.\n7. Participation in other drug clinical trials within 3 months prior to enrollment.",{"count":81,"type":22},140,[25],"This study aims to evaluate the clinical efficacy of Danhong injection in patients with septic myocardial injury through a prospective randomized controlled trial. The study will enroll 140 patients meeting criteria for septic myocardial injury, divided into a Danhong injection group and a placebo group. Primary endpoints include changes in myocardial injury markers and improvement rates in cardiac function over 7 days, while secondary endpoints include 28-day mortality rates. This will determine whether Danhong injection possesses myocardial protective effects and provide evidence-based support for expanding its clinical indications.",[85],"Sepsis-Induced Myocardial Dysfunction","2026-01-22",{"date":88,"type":40},"2026-01-29",{"date":90,"type":22},"2026-07-01",{"date":92,"type":22},"2028-12-01",{"name":94,"class":47},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine"]